camptothecin has been researched along with magnolol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Cao, Y; Ge, G; Li, C; Li, W; Sun, X; Xiao, L; Zhu, L | 1 |
2 other study(ies) available for camptothecin and magnolol
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Camptothecin; Enzyme Inhibitors; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Lignans; Metabolic Networks and Pathways; Microsomes, Liver; Recombinant Proteins; Serum Albumin, Bovine; UDP-Glucuronosyltransferase 1A9 | 2018 |